rs20455
Variant summary
Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_145027.6(KIF6):c.2155T>C(p.Trp719Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.386 in 1,611,174 control chromosomes in the GnomAD database, including 129,068 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as drug response (★★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely benignin UniProt.
Frequency
Consequence
NM_145027.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
KIF6 | NM_145027.6 | c.2155T>C | p.Trp719Arg | missense_variant | 19/23 | ENST00000287152.12 | NP_659464.3 | |
LOC107986594 | XR_001744111.2 | n.219+5354A>G | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
KIF6 | ENST00000287152.12 | c.2155T>C | p.Trp719Arg | missense_variant | 19/23 | 2 | NM_145027.6 | ENSP00000287152 | P1 |
Frequencies
GnomAD3 genomes AF: 0.489 AC: 74283AN: 151892Hom.: 21067 Cov.: 31
GnomAD3 exomes AF: 0.405 AC: 101846AN: 251262Hom.: 22539 AF XY: 0.400 AC XY: 54334AN XY: 135788
GnomAD4 exome AF: 0.376 AC: 548109AN: 1459164Hom.: 107970 Cov.: 32 AF XY: 0.376 AC XY: 273110AN XY: 726034
GnomAD4 genome AF: 0.489 AC: 74366AN: 152010Hom.: 21098 Cov.: 31 AF XY: 0.485 AC XY: 36000AN XY: 74288
ClinVar
Submissions by phenotype
pravastatin response - Efficacy Other:1
drug response, reviewed by expert panel | curation | PharmGKB | Mar 24, 2021 | PharmGKB Level of Evidence 2B: Variants in Level 2B clinical annotations are not in PharmGKB’s Tier 1 VIPs. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2B clinical annotations must be supported by at least two independent publications. Drug-variant association: Efficacy |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at